PetVivo Holdings to Showcase Veterinary Medical Innovations at Spartan Capital Investor Conference
PetVivo Holdings will present its innovative veterinary medical devices at the Spartan Capital Securities investor conference, highlighting the company's growth potential in the animal healthcare market.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), a biomedical therapeutics provider for equines and companion animals, will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The company's participation signals its position as an emerging market leader in veterinary medical technology and provides a platform to connect with institutional investors seeking growth opportunities in the animal healthcare sector.
Chief Executive Officer John Lai will present an overview of PetVivo's operations and discuss its flagship products, SPRYNG™ with OsteoCushion™ Technology and PrecisePRP®. SPRYNG with OsteoCushion Technology represents an innovative approach to joint pain management in animals. The intra-articular injectable veterinary medical device consists of sterilized, extra-cellular matrix microparticles that adsorb onto the joint synovial lining and integrate with subsynovial tissue. This mechanism promotes restoration of proper joint mechanics and aids in managing noninfectious sources of joint pain, including joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP marks a significant advancement in veterinary platelet-rich plasma treatments as a first-in-class off-the-shelf product designed for veterinarian use. Unlike traditional PRP mechanical kits requiring blood draws and centrifugation, PrecisePRP offers a leucoreduced, allogeneic, pooled, freeze-dried PRP that provides species-specific concentrated platelets for intra-articular administration in dogs and horses. The product guarantees uniformity and consistency with each vial containing 4 billion platelets at a concentration of 500,000 platelets per microliter and leucoreduction maintaining less than 1500 white blood cells per microliter.
John D. Lowry, Founder and Chief Executive Officer of Spartan Capital Securities, LLC, emphasized the conference's mission to connect growth companies with appropriate investors. The event, organized in partnership with B2i Digital, will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend, creating substantial networking opportunities for participating companies. For more information about the conference and registration details, please visit https://spartancapital.com.
David Shapiro, CEO of B2i Digital, noted that PetVivo's participation aligns with their commitment to connecting investors with diverse growth companies. The conference will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions designed to facilitate meaningful dialogue between growth companies and the investment community. This platform becomes particularly important for biomedical companies like PetVivo that require substantial capital investment for research, development, and market expansion of their veterinary medical innovations.
The investor conference comes at a crucial time for veterinary medical technology companies seeking to expand their market presence and secure funding for continued innovation. PetVivo's presentation opportunity provides visibility within the investment community that could accelerate growth and market adoption of their veterinary medical devices. The company's focus on leveraging human therapies for companion animal treatment represents a growing trend in the veterinary medical field, where accelerated timelines to market for medical devices compared to more stringently regulated pharmaceuticals offer competitive advantages.